NEO stock sentiment todayNeoGenomics, Inc.
Sentiment verdict
Gossip first, financials second — HOT at 85% confidence.
Last updated · cached analysis, refreshes periodically
NEO
NeoGenomics, Inc.NeoGenomics has hit a critical inflection point, turning GAAP profitable while hitting 52-week highs, signaling a fundamental shift from a growth-at-all-costs story to a sustainable margin-expansion play.
Pick a name and you can add your own 1-, 3- and 6-month price calls — no account needed. The needle above shows where the crowd sits. Calls lock 48 hours after you make them, so every scorecard stays honest.
You'll show up on boards and The Floor under this name. Add an email later to keep your history.
No account needed. You can add an email later to keep your calls.
Already have an account? Sign in
See exactly how analyst targets, gossip sentiment and momentum are weighted into this 6-month forecast.
Sign in to go Pro →Full model breakdown (analyst / gossip / momentum weights) is a Pro feature. Modelled for NEO. Not financial advice.
Price · last 12 months
Gossip
The narrative has shifted from recovery to outperformance. Recent headlines highlight a 52-week high surge driven by the company's first move into profitability and improving margins. The upcoming Morgan Stanley conference appearance is being viewed as a potential catalyst for institutional re-rating.
- ·First-time profitability milestone
- ·52-week high momentum
- ·Institutional validation (Morgan Stanley conference)
- ·Improved margin expansion narrative
Financial
NEO has successfully executed its turnaround plan, focusing on high-value Next-Generation Sequencing (NGS) and clinical services. Revenue growth remains robust in the low double-digits, and the transition to positive net income marks a significant de-risking of the balance sheet.
- ·Positive GAAP Net Income pivot
- ·Consistent double-digit revenue growth
- ·Strengthening EBITDA margins
- ·Reduced cash burn
Conviction
Whose money is actually in the stock — insider open-market trades and the patience of the institutional holder base.
Mixed conviction — no decisive signal from insiders or the holder base.
- ·Insiders sold a net $321K on the open market in the last 120 days.
Pro shows every named insider trade in the window (buyer, title, size, price, and whether it was a pre-scheduled 10b5-1 sale) plus the full holder register split into patient capital and fast money.
Unlock with Pro →Source: SEC EDGAR Form 4 + 13F holder register. Option exercises, grants, gifts and tax withholding are excluded — only open-market purchases and sales count. Not financial advice.
Risks
- ·High sensitivity to Medicare reimbursement rate changes
- ·Intense competition in the oncology testing space
- ·Potential regulatory changes regarding LDT (Laboratory Developed Tests)
Peer temperature
How direct competitors stack up against NEO right now.
- NEUTRALEXASExact Sciences Corp
COLD — while larger, it faces higher customer acquisition costs and lacks NEO's recent pivot to immediate GAAP profitability.
See full analysis → - COLDNVTAInvitae Corporation
COLDER — struggling with significant liquidity issues and restructuring that makes NEO’s stable balance sheet far more attractive.
See full analysis → - NEUTRALGHGuardant Health
NEUTRAL — trading at a higher price-to-sales multiple with deeper losses, despite having a leading position in liquid biopsy.
See full analysis →
- NEO+10.5%
- EXAS—
- NVTA—
- GH-1.1%
Analyst price target
Consensus average of 8 analysts · median 19.00
Source: StockAnalysis.com · updated 2026-08-27
Recent headlines
- Stock TitanNeo-Concept (NCI) CEO gets 140K Class B shares at par
- kalkine.caNeo Performance Materials Stock Under Pressure — Is Rare Earth Momentum Losing Steam?
- Yahoo FinanceNeoGenomics (NEO) Soars 7.2%: Is Further Upside Left in the Stock?
- Quiver Quantitative$NEO stock is up 10% today. Here's what we see in our data.
- StockStoryWhy NeoGenomics (NEO) Stock Is Up Today
- StocktwitsWhy Did SJM, REPL, NEO Stocks Surge To 52-Week Highs Today?
AI-generated analysis for informational purposes only. Not financial advice.